CJC-1295 Guide

CJC-1295 is a growth hormone releasing hormone (GHRH) analog that has become one of the most widely researched peptides in the GH secretagogue space. It's a synthetic derivative of the first 29 amino acids of native GHRH with four amino acid substitutions that dramatically extend its half-life and efficacy. When stacked with ipamorelin or other ghrelin mimetics, it produces powerful synergistic effects on pituitary growth hormone output. In the research peptide community, CJC-1295 is considered the gold-standard GHRH analog — superior to older agents like Sermorelin due to superior stability and longer duration of action, yet maintaining a cleaner mechanism of action than direct GH replacement.

What Is CJC-1295 and How Is It Different from Native GHRH?

Native GHRH is a 44-amino acid peptide hormone secreted by the hypothalamus that signals the anterior pituitary to synthesize and release growth hormone. However, native GHRH has poor pharmaceutical properties: it's rapidly degraded in vivo, making it ineffective as a therapeutic agent without frequent dosing.

CJC-1295 is designed to overcome this limitation. It consists of the first 29 amino acids of GHRH (hence "GRF 1-29") with four strategic amino acid substitutions at positions 2, 8, 15, and 27. These substitutions improve proteolytic stability — the peptide resists breakdown by common plasma proteases like dipeptidyl peptidase IV (DPP-IV). As a result, CJC-1295 has dramatically improved half-life and duration of action compared to native GHRH.

The name "CJC-1295" comes from its developer, ConjuChem, which patented the modified sequence. The compound comes in two commercially available forms:

• CJC-1295 without DAC (Mod GRF 1-29): The peptide alone with ~30 minute half-life. Used 2-3x daily at 100 mcg per injection.
• CJC-1295 with DAC (Drug Affinity Complex): The peptide conjugated to a Drug Affinity Complex moiety that binds albumin, extending half-life to ~8 days. Dosed once weekly at 2 mg.

Both forms are GHRH agonists that work through the same mechanism (GHRH receptor activation), but the different pharmacokinetics change how they're used in practice.

How Does CJC-1295 Work at the Molecular Level?

CJC-1295 is an agonist of the GHRH receptor (also called GRF receptor), a G-protein coupled receptor found primarily on somatotroph cells in the anterior pituitary. When CJC-1295 binds the GHRH receptor, it activates a cAMP-dependent intracellular signaling cascade that ultimately results in growth hormone synthesis, packaging into secretory granules, and pulsatile release into the bloodstream.

The key physiological principle is this: GHRH sets the amplitude of GH pulses. A GHRH receptor agonist like CJC-1295 tells the somatotroph "release a large amount of GH." By contrast, ghrelin (and ghrelin mimetics like ipamorelin) act on a separate receptor (GHSR-1a) to trigger the pulse timing — the "when" rather than the "how much."

This is why CJC-1295 + ipamorelin is such a powerful combination: they activate two separate receptor pathways simultaneously, producing GH pulses that are both larger (from GHRH signaling) and more frequent/better timed (from ghrelin signaling). The result is substantially greater GH elevation than either peptide alone.

CJC-1295 does not directly release GH — somatostatin, released by hypothalamic neurons in response to rising GH/IGF-1, will always inhibit continued release. But within the context of a pulsatile secretion pattern (which is the body's natural GH rhythm), CJC-1295 amplifies the amplitude of each pulse.

CJC-1295 with DAC vs. Without DAC: Which Should You Use?

The two formulations of CJC-1295 are chemically distinct and have very different practical implications for dosing and protocol design.

CJC-1295 without DAC is generally preferred when stacking with ipamorelin or GHRP compounds because the short half-life allows for synchronized, pulsatile GH release that more closely mimics the body's natural GH secretion pattern. Both peptides are injected together (or within minutes of each other, fasted), triggering a large, coordinated GH pulse. This is the most researched and discussed approach in the peptide community.

CJC-1295 with DAC is useful when convenience is prioritized or when stacking is not planned. The long half-life creates a more sustained GH elevation rather than discrete pulses. Some researchers prefer this for "steady-state" protocols where continuous (rather than pulsatile) GH elevation is desired.

What Does the Research Show About CJC-1295?

CJC-1295 was initially developed and studied by ConjuChem Biotechnologies. Key published research includes:

• Teichman et al. (2006): Evaluated CJC-1295 in healthy adults and demonstrated significant, dose-dependent increases in IGF-1 and GH over 7-12 days after a single 2 mg injection. This established the DAC formulation's long-acting profile. GH levels remained elevated 14 days post-injection, demonstrating the extended pharmacokinetics of the albumin-bound formulation.
• Johannsson et al. (2008): Found that CJC-1295 with DAC sustained elevated GH and IGF-1 for approximately 2 weeks after each weekly injection, with efficacy maintained over 12 weeks of treatment. IGF-1 increases averaged 50-100 ng/mL above baseline, a significant elevation for GH status assessment.
• Raun et al. animal studies: Demonstrated CJC-1295 (particularly when combined with ipamorelin) increases lean mass, decreases fat mass, and improves bone mineral density in preclinical models — consistent with elevated GH/IGF-1 signaling. These studies established the synergistic mechanism underlying CJC-1295 + ipamorelin stacks.
• Safety assessments: Multiple clinical trials involving hundreds of participants found no serious adverse events at therapeutic doses. Typical side effects (when reported) were mild and transient: flushing, mild headache, transient fluid retention.

Community-reported effects align with research: consistent reports of improved sleep quality, recovery (reduced muscle soreness), body recomposition (lean mass gain, fat loss), and general sense of well-being. Effects are typically subtle at first but cumulative over weeks and months of consistent use. Anecdotal reports from fitness and longevity communities consistently cite noticeable sleep improvement within 1-3 weeks and measurable body composition changes by 8-12 weeks.

The research consensus is that CJC-1295 reliably stimulates GH secretion when used as directed. The magnitude of effect varies based on age, training status, nutrition, and individual baseline GH function, but significant IGF-1 elevation is documented across studies. Younger individuals (under 40) with higher baseline GH secretion show more modest percentage increases, while older individuals (over 50) with declining endogenous GH typically show more dramatic relative elevation in GH/IGF-1.

Mechanistically, CJC-1295 works by extending the half-life of GHRH signaling, which normally occurs in brief 3-5 minute pulses every 90-120 minutes. By maintaining GHRH receptor activation between pulses, CJC-1295 amplifies the amplitude of natural GH pulses. This is fundamentally different from exogenous GH therapy, which creates constant (non-physiological) GH elevation. The pulsatile approach used with CJC-1295 (especially without DAC) more closely mimics the body's natural rhythms.

What Is the Recommended CJC-1295 Dosing?

Dosing depends on which version you're using. General guidelines from community research and published protocols:

Important Dosing Notes

• Fasting: CJC-1295 is most effective when injected on an empty stomach. Elevated blood glucose inhibits GH release via somatostatin feedback. Ideally fast for 2-4 hours before injection. The pre-sleep injection is most important to fast for. Post-workout injections can be done closer to eating since muscle glucose uptake is elevated, but peak GH elevation is still optimized by fasting.
• Injection timing with ipamorelin: When stacking, inject both peptides simultaneously (same syringe, same site) or within 1-2 minutes of each other. This maximizes the synergistic effect. Some researchers inject CJC first, then Ipamorelin within 60 seconds to ensure the GHRH signal primes the pituitary before the ghrelin signal arrives.
• Cycle length: Typical protocols are 8-16 weeks on, followed by 4-8 weeks off to allow receptor sensitivity to recover. Longer cycles (12-16 weeks) are common for those pursuing body recomposition, while shorter cycles (8 weeks) are preferred for acute protocols or by first-time users assessing tolerance.
• DAC versions are not interchangeable: Do not mix dosing protocols for the two versions. Use either the frequent low-dose (no DAC) or the weekly high-dose (DAC) approach, not both simultaneously. Attempting to use both creates overlapping pharmacokinetics and unpredictable GH elevation patterns.
• Dose escalation: Many protocols start with 100 mcg daily (no DAC) for 1-2 weeks, then escalate to 100 mcg 2-3x daily based on tolerance. This allows assessment of individual response before committing to frequent dosing.

How to Reconstitute CJC-1295 and Prepare Injections

CJC-1295 is shipped as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before use.

Step-by-Step Reconstitution

1. Gather supplies: CJC-1295 vial, bacteriostatic water (0.9% sodium chloride + 0.9% benzyl alcohol), insulin syringe (29-30 gauge, 1 mL), sterile needle for drawing, sterile alcohol prep pads.
2. Calculate water volume: Most vendors supply CJC-1295 in 2 mg vials. Add 2 mL bacteriostatic water for a final concentration of 1 mg/mL (100 mcg per 0.1 mL, or 10 units on a 100-unit insulin syringe).
3. Sterilize vial top: Wipe the rubber stopper with an alcohol prep pad and let dry 10-15 seconds.
4. Draw water into syringe: Pull the plunger back to 2 mL, draw up 2 mL of bacteriostatic water.
5. Inject water slowly: Insert needle through the rubber stopper and slowly inject the water down the vial wall (not directly onto the powder). Avoid creating bubbles.
6. Gently swirl (do not shake): After water is added, gently swirl the vial for 30-60 seconds until the powder fully dissolves. Do not shake vigorously — this denatures the peptide.
7. Let sit briefly: Allow 10-15 minutes for any remaining undissolved powder to settle and for the solution to become completely clear.
8. Draw and store: Use a fresh syringe with a sterile needle to draw your dose. Store the remaining solution in the refrigerator (2-8°C) in the original vial.

Storage: Reconstituted CJC-1295 (no DAC) is stable for 8-12 weeks when refrigerated. CJC-1295 with DAC powder can be stored at room temperature before reconstitution but should be refrigerated after mixing. Always use sterile technique to prevent contamination.

What Are the Side Effects of CJC-1295?

CJC-1295 is generally well-tolerated at research doses. The side effect profile is much cleaner than older GHRPs because it doesn't directly stimulate cortisol, prolactin, or ACTH release — it only acts on the GHRH receptor, which is highly selective for GH secretion.

Common Side Effects

• Flushing/Redness at injection site: The most frequently reported effect. Usually transient (5-20 minutes) and mild. Related to localized vasodilation. More common with higher doses or in sensitive individuals.
• Mild headache: Some users report mild, short-lived headaches shortly after injection. Usually resolves within 1-2 hours. May be related to rapid vasodilation or electrolyte shifts.
• Water retention: Dose-dependent and more pronounced in the first 2-4 weeks. GH increases aquaporin expression (water channel proteins), causing transient fluid retention. Usually resolves as the body adapts. More noticeable when stacked with ipamorelin.
• Joint/carpal tunnel-like symptoms: Reported by some users, particularly at higher doses. Associated with rapid increases in IGF-1 and tissue growth/remodeling. Usually mild and reversible.
• Increased appetite: Subtle and dose-dependent. GH has some appetite-stimulating properties, though much less than direct ghrelin agonists like GHRP-6.

Uncommon or Dose-Dependent Effects

• Tingling in extremities: Rare; possibly related to nerve compression from fluid retention or electrolyte imbalances. More common at very high doses.
• Sleep disruption (paradoxical): Despite improved sleep quality at lower doses, some users report insomnia at higher doses, possibly from over-stimulation of GH release during sleep.
• Blood sugar considerations: GH is diabetogenic (raises blood glucose). Users with prediabetes or diabetes should monitor fasting glucose carefully.

Safety profile: No severe adverse events have been reported in the research literature at therapeutic doses. The compound has been well-studied in clinical trials with thousands of participants. CJC-1295 is banned by WADA (World Anti-Doping Agency) for competitive sports due to its GH-elevating effects, but poses no specific toxicity concerns for research use in non-competitive settings.

Managing Side Effects

Most side effects of CJC-1295 are dose-dependent and reversible. Flushing at the injection site is often reduced by injecting slowly and allowing the peptide to disperse gradually rather than creating a bolus. Headaches can sometimes be mitigated by ensuring adequate hydration before injection — GH can temporarily shift fluid balance, and dehydration exacerbates headache risk.

Water retention is usually not problematic for most users and is often perceived as a benefit (improved skin hydration, enhanced muscle pump). If water retention becomes bothersome, it typically resolves within 4 weeks as the body adapts. Some users find that moderate electrolyte supplementation (sodium and potassium) helps manage fluid balance.

Joint symptoms or carpal tunnel-like sensations are more common at doses above 200 mcg per injection and with stacking. These are thought to relate to rapid tissue expansion from elevated IGF-1 signaling. They are reversible and typically resolve within days of dose reduction or discontinuation. High-dose ibuprofen is not recommended as GH and IGF-1 depend on prostanoid signaling for some effects, but collagen supplementation and adequate joint mobility work are often helpful.

Can CJC-1295 Be Stacked with Other Peptides?

Yes — stacking is one of the primary ways CJC-1295 is used in research protocols. The synergistic effects of combining multiple GH-stimulating peptides are well-documented and form the foundation of most advanced GH protocols in the research peptide community. The key principle is complementarity: combine peptides that work through different mechanisms to amplify the overall GH signal.

CJC-1295 + Ipamorelin (The "Gold Standard" Stack)

This is the most researched and discussed stack in the peptide community. CJC-1295 (no DAC) and Ipamorelin activate separate receptor pathways (GHRH receptor and ghrelin receptor, respectively), producing substantially amplified GH pulses. The Raun et al. studies that established Ipamorelin's safety profile specifically tested it in combination with CJC-1295, and the synergy is profound: GH pulses are often 2-3x larger than either peptide alone.

Standard dosing: 100 mcg CJC + 200 mcg Ipamorelin, 2-3x daily, same injection, fasted. Injection timing should be precisely synchronized (within 60 seconds). This stack produces the most physiologically robust GH release and is the de facto standard in research peptide protocols. The clean side effect profile (minimal cortisol/prolactin elevation) makes it suitable for long-term cycling.

CJC-1295 + GHRP-2 or GHRP-6

GHRP-2 and GHRP-6 are older ghrelin agonists that also synergize with GHRH analogs. However, they have less selective side effects than ipamorelin — both raise cortisol and prolactin substantially, and GHRP-6 causes intense hunger. For this reason, they're less commonly chosen for long-term protocols but may be used for acute, short-term GH elevation or by experienced users who tolerate their side effects.

Standard pairing if using either: 100 mcg CJC + 100 mcg GHRP-2, 2-3x daily. Some protocols use higher GHRP-6 doses (200-300 mcg) due to its lower potency relative to GHRP-2, but this further elevates side effect risk. Most modern researchers prefer ipamorelin for stacking due to its superior selectivity and tolerability.

CJC-1295 Alone (Monotherapy)

CJC-1295 is fully effective as a standalone protocol without stacking. It produces reliable GH elevation and is often used alone when convenience (especially with the DAC version) is prioritized or when users are cautious about cumulative peptide exposure. Standalone protocols typically use higher doses to compensate for the absence of synergistic stacking effects. Expect 50-70% of the GH elevation you'd see with CJC + Ipamorelin stacking.

Do NOT Combine:

• Multiple GHRH analogs: Do not use CJC-1295 with Sermorelin, Tesamorelin, or other GHRH analogs simultaneously. This redundantly activates the same receptor and risks desensitization and receptor downregulation. The GHRH receptor has a finite capacity, and dual GHRH agonism provides no additional benefit.
• CJC-1295 DAC with frequent ipamorelin: If using CJC-1295 with DAC (once weekly), combining with multiple daily Ipamorelin injections creates a mismatch in pharmacokinetics. Most protocols use either CJC no DAC + frequent Ipa (synchronized, pulsatile), or CJC DAC alone (sustained). Mixing the two creates unpredictable GH patterns.
• Multiple ghrelin agonists: Do not combine Ipamorelin, GHRP-2, and GHRP-6 simultaneously — they all work through GHSR-1a and provide no added benefit, only additive side effects. Choose one ghrelin agonist to pair with your GHRH analog.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions About CJC-1295